Liquidia Technologies is trading 4% up now at $74.07 as investors continue to respond to recently upgraded fair value estimates and price targets following strong earnings and Yutrepia-driven growth.
- The stock is rebounding from last week’s biotech sector profit-taking, supported by analysts’ revised models and higher fair value estimates.
- Today's upward move demonstrates relative strength for the company despite broader weakness in the XBI biotech index.